In an exploratory analysis, we evaluated the influence of baseline CRP levels (high vs low) across the two main immunotherapy strategies in NSCLC, that is, Chemo-ICI versus ICI alone. The gene discussed is CRP; the disease is non-small cell lung carcinoma.